Jack Rasmussen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jack Rasmussen has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Mete Erdogan
Department of Trauma Nova Scotia, Dalhousie University, Halifax, Canada
2 shared publicationsRobert S Green
Department of Trauma Nova Scotia, Dalhousie University, Halifax, Canada
2 shared publicationsA. Amaral
Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
1 shared publicationA. El Khatib
Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
1 shared publicationA. Papp
BC Professional Firefighters' Burn Unit, Vancouver General Hospital, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
1 shared publication- Alan David Rogers
Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre , Toronto, ON M4N 3M5
1 shared publication
Latest Publications
- Open Access
- 8 May 2025
- Published by SAGE Publications in Plastic Surgery
- Vol. 34 (2) , 354-360
Integra Dermal Regeneration Template in Reconstruction of Primary Oncologic Defects in the Lower Extremities: A Case Series
This article presents a case series of 4 patients who underwent primary reconstruction of oncologic defects in the lower extremities using Integra Dermal Regeneration Template (IDRT). The patients had either primary or recurrent tumors, which resulted in exposure of deep underlying structures including tendon, nerve, muscle, and bone. IDRT was selected to manage these defects due to the uncertain malignant potential of tissue margins and its ability to facilitate later margin revision without sacrificing tissue. The use of IDRT allowed for the growth of a neodermis that supported subsequent split-thickness skin grafting in all cases. Additionally, for those with positive margins, surgical revision and skin graft application was able to be performed in a single procedure, maximizing operating room use and patient convenience. This case series highlights the potential of IDRT in managing complex oncologic defects in the lower extremities, expanding options for reconstructive surgeons. Key findings: (1) IDRT is a viable option for reconstruction in oncologic resections exposing deep structures. (2) In cases with unknown malignant potential of tissue margins, use of IDRT can allow for revision of positive margins without sacrificing graft or flap tissue. (3) Negative pressure wound therapy is an important adjunct in achieving a favorable neodermis for acceptance of a spilt thickness skin graft.
- 8 May 2025
- Published by SAGE Publications in Plastic Surgery
- Vol. 34 (2) , 354-360
Open AccessIntegra Dermal Regeneration Template in Reconstruction of Primary Oncologic Defects in the Lower Extremities: A Case Series
This article presents a case series of 4 patients who underwent primary reconstruction of oncologic defects in the lower extremities using Integra Dermal Regeneration Template (IDRT). The patients had either primary or recurrent tumors, which resulted in exposure of deep underlying structures including tendon, nerve, muscle, and bone. IDRT was selected to manage these defects due to the uncertain malignant potential of tissue margins and its ability to facilitate later margin revision without sacrificing tissue. The use of IDRT allowed for the growth of a neodermis that supported subsequent split-thickness skin grafting in all cases. Additionally, for those with positive margins, surgical revision and skin graft application was able to be performed in a single procedure, maximizing operating room use and patient convenience. This case series highlights the potential of IDRT in managing complex oncologic defects in the lower extremities, expanding options for reconstructive surgeons. Key findings: (1) IDRT is a viable option for reconstruction in oncologic resections exposing deep structures. (2) In cases with unknown malignant potential of tissue margins, use of IDRT can allow for revision of positive margins without sacrificing graft or flap tissue. (3) Negative pressure wound therapy is an important adjunct in achieving a favorable neodermis for acceptance of a spilt thickness skin graft.
- Open Access
- 13 March 2025
- Published by SAGE Publications in Plastic Surgery
- Vol. 34 (2) , 301-305
Current Best Evidence for 5 Promising Medications Used for Scar Minimization Therapy
Introduction: Wound healing by fibrosis allows for closure of a wound, but leaves behind a permanent scar with physical and psychological effects. The primary aim of this narrative review was to summarize the current status of the evidence supporting the use of oral or topical medications to minimize scarring in humans. Methods: With the help of a health sciences librarian, PubMed, Embase, and Scopus were searched up to March 31, 2023, to investigate potential medications to ameliorate scarring. Based on this search, the medications pirfenidone, losartan, trichostatin A, enalapril, and atorvastatin were identified as 5 therapies with the most research to support their use. Studies discussing noncutaneous scarring (myocardial, intraabdominal, etc) or in animal models were excluded. Results: There is a paucity of quality literature describing the use of oral or topical medications to minimize fibrosis and produce more favorable scarring. Six studies describing the medications listed above all demonstrated an improvement in scarring parameters, most commonly based on the Vancouver Scar Scale. Conclusions: Though preliminary, emerging evidence suggests that therapies already exist with the potential to improve cutaneous scarring. Some of these medications are already ubiquitous, affordable and have a known safety profile. Excitingly, these treatments are either oral or topical, meaning that they are more accessible for patients than some current modalities for scar treatment, including steroid injections or laser therapy. Further larger-scale trials are needed before these treatments can be recommended as a routine part of scar management.
- 13 March 2025
- Published by SAGE Publications in Plastic Surgery
- Vol. 34 (2) , 301-305
Open AccessCurrent Best Evidence for 5 Promising Medications Used for Scar Minimization Therapy
Introduction: Wound healing by fibrosis allows for closure of a wound, but leaves behind a permanent scar with physical and psychological effects. The primary aim of this narrative review was to summarize the current status of the evidence supporting the use of oral or topical medications to minimize scarring in humans. Methods: With the help of a health sciences librarian, PubMed, Embase, and Scopus were searched up to March 31, 2023, to investigate potential medications to ameliorate scarring. Based on this search, the medications pirfenidone, losartan, trichostatin A, enalapril, and atorvastatin were identified as 5 therapies with the most research to support their use. Studies discussing noncutaneous scarring (myocardial, intraabdominal, etc) or in animal models were excluded. Results: There is a paucity of quality literature describing the use of oral or topical medications to minimize fibrosis and produce more favorable scarring. Six studies describing the medications listed above all demonstrated an improvement in scarring parameters, most commonly based on the Vancouver Scar Scale. Conclusions: Though preliminary, emerging evidence suggests that therapies already exist with the potential to improve cutaneous scarring. Some of these medications are already ubiquitous, affordable and have a known safety profile. Excitingly, these treatments are either oral or topical, meaning that they are more accessible for patients than some current modalities for scar treatment, including steroid injections or laser therapy. Further larger-scale trials are needed before these treatments can be recommended as a routine part of scar management.
- 6 June 2021
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 43 (2) , 462-467
The Use of Extracorporeal Membrane Oxygenation in Severely Burned Patients: A Survey of North American Burn Centers
Respiratory failure and acute respiratory distress syndrome can occur in burn patients with or without inhalational injury and can significantly increase mortality. For patients with severe respiratory failure who fail conventional therapy with mechanical ventilation, the use of venovenous extracorporeal membrane oxygenation (ECMO) may be a life-saving salvage therapy. There have been a series of case reports detailing the use of ECMO in burn patients over the last 20 years, but very little is currently known about the status of ECMO use at burn centers in North America. Using a web-based survey of burn center directors in Canada and the United States, we examined the rate of usage of ECMO in burn care, barriers to its use, and the perioperative management of burn patients receiving ECMO therapy. Our findings indicate that approximately half of the burn centers have used ECMO in the care of burn patients, but patient volume is very low on average (less than 1 per year). Of centers that do use ECMO in burn care, only 40% have a specified protocol for doing so. Approximately half have operated on patients being actively treated with ECMO therapy, but perioperative management of anticoagulation varies widely. A lack of experience and institutional support and a perceived lack of evidence to support ECMO use in burn patients were the most commonly identified barriers to more widespread uptake. Better collaboration between burn centers will allow for the creation of consensus statements and protocols to improve outcomes for burn patients who require ECMO.
- 6 June 2021
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 43 (2) , 462-467
The Use of Extracorporeal Membrane Oxygenation in Severely Burned Patients: A Survey of North American Burn Centers
Respiratory failure and acute respiratory distress syndrome can occur in burn patients with or without inhalational injury and can significantly increase mortality. For patients with severe respiratory failure who fail conventional therapy with mechanical ventilation, the use of venovenous extracorporeal membrane oxygenation (ECMO) may be a life-saving salvage therapy. There have been a series of case reports detailing the use of ECMO in burn patients over the last 20 years, but very little is currently known about the status of ECMO use at burn centers in North America. Using a web-based survey of burn center directors in Canada and the United States, we examined the rate of usage of ECMO in burn care, barriers to its use, and the perioperative management of burn patients receiving ECMO therapy. Our findings indicate that approximately half of the burn centers have used ECMO in the care of burn patients, but patient volume is very low on average (less than 1 per year). Of centers that do use ECMO in burn care, only 40% have a specified protocol for doing so. Approximately half have operated on patients being actively treated with ECMO therapy, but perioperative management of anticoagulation varies widely. A lack of experience and institutional support and a perceived lack of evidence to support ECMO use in burn patients were the most commonly identified barriers to more widespread uptake. Better collaboration between burn centers will allow for the creation of consensus statements and protocols to improve outcomes for burn patients who require ECMO.
- 10 September 2020
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 42 (2) , 345-347
Successful Use of Extracorporeal Membrane Oxygenation Therapy in Patients With 80% Full Thickness Burns
Despite advances in burn care, mortality in adult patients with extensive burn injuries remains a concern, particularly in those who develop concurrent acute respiratory distress syndrome (ARDS). In cases of ARDS refractory to conventional treatments, venovenous extracorporeal membrane oxygenation (ECMO) may represent a viable salvage therapy, even in the major burn population. We present the case of a 38-year-old man with full thickness burns to over 80% of his body, who developed severe ARDS 4 days postburn. After failing to respond to deep sedation, paralysis, and proning, ECMO therapy was initiated to maintain oxygenation and ventilation. Over the next 14 days, while the patient was treated with ECMO, he successfully underwent three major operations to debride and allograft approximately 65% of his body surface area, including one in the prone position. ECMO therapy was discontinued on postburn day 18, and the patient had his wounds reconstructed and survived his injuries. To the best of our knowledge, this is the first report of a burn patient with such severe burns requiring surgical intervention that has been treated with ECMO and survived, and the first case of a burn patient on ECMO having surgery in the prone position. They conclude this case serves as a “proof of concept” that ECMO is a potential treatment for appropriately selected major burn patients with ARDS who fail to respond to other therapies.
- 10 September 2020
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 42 (2) , 345-347
Successful Use of Extracorporeal Membrane Oxygenation Therapy in Patients With 80% Full Thickness Burns
Despite advances in burn care, mortality in adult patients with extensive burn injuries remains a concern, particularly in those who develop concurrent acute respiratory distress syndrome (ARDS). In cases of ARDS refractory to conventional treatments, venovenous extracorporeal membrane oxygenation (ECMO) may represent a viable salvage therapy, even in the major burn population. We present the case of a 38-year-old man with full thickness burns to over 80% of his body, who developed severe ARDS 4 days postburn. After failing to respond to deep sedation, paralysis, and proning, ECMO therapy was initiated to maintain oxygenation and ventilation. Over the next 14 days, while the patient was treated with ECMO, he successfully underwent three major operations to debride and allograft approximately 65% of his body surface area, including one in the prone position. ECMO therapy was discontinued on postburn day 18, and the patient had his wounds reconstructed and survived his injuries. To the best of our knowledge, this is the first report of a burn patient with such severe burns requiring surgical intervention that has been treated with ECMO and survived, and the first case of a burn patient on ECMO having surgery in the prone position. They conclude this case serves as a “proof of concept” that ECMO is a potential treatment for appropriately selected major burn patients with ARDS who fail to respond to other therapies.